Scientific process, pharmacology and drug discovery

Current Opinion in Pharmacology

Volumn 11, Issue 5, 2011, Pages 528-533

  Trist, David G ^a  

^a NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE; BUNGAROTOXIN RECEPTOR; CITALOPRAM; DRUG RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCINE RECEPTOR ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC M4 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; PHOSPHOTRANSFERASE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VOFOPITANT;

ARTICLE; DRUG DEVELOPMENT; DRUG TARGETING; GENOMICS; HEALTH CARE PERSONNEL; HUMAN; HYPOTHESIS; NON INVASIVE MEASUREMENT; NONHUMAN; PHARMACOLOGIST; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEOMICS; SCIENTIFIC PROCESS; SOCIAL PHOBIA; STUDY DESIGN; TARGET IDENTIFICATION; TARGET VALIDATION; TECHNIQUE; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

EID: 80053100399     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2011.05.008     Document Type: Review

References (37)

1. M. Weatherall Scientific Method 1968 The English Universities Press Ltd.
2. B. Clegg The First Scientist: A Life of Roger Bacon 2003 Constable & Robinson
3. R.S. Westfall Isaac Newton 2007 Cambridge University Press
4. S. Gattei Karl Popper's philosophy of science Routledge Studies in the Philosophy of Science vol. 5 2009
5. E. Ratti, and D. Trist Continuing evolution of the drug discovery process in the pharmaceutical industry Pure Appl Chem 73 2001 67 75
6. S.E. Hyman, and W.S. Fenton What are the right targets for psychopharmacology? Science 299 2003 350 351 (Pubitemid 36120025)
7. J. Orloff, F. Douglas, J. Pinheiro, S. Levinson, M. Branson, P. Chaturvedi, E. Ette, P. Gallo, G. Hirsch, and C. Mehta The future of drug development: advancing clinical trial design Nat Rev, Drug Discov 8 2009 949 957
8. G. Miller Is Pharma running out of brainy ideas? Science 329 2010 502 504
9. D. Trist, E. Ratti, and L. Da Ros The apparent declining efficiency of drug discovery J.B. Taylor, D.J. Triggle, P.D. Kennewell, Comprehensive Medicinal Chemistry II 2007 Elsevier 615 625
10. P. Vallance, and T.G. Smart The future of pharmacology Br J Pharm 147 2006 S304 S307
11. M.N. Pangalos, L.E. Schechter, and O. Hurko Drug development for CNS disorders: strategies for balancing risk and reducing attrition Nat Rev, Drug Discov 6 2007 521 532 (Pubitemid 47019441)
12. P.M. Matthews, G.D. Honey, and E.T. Bullmore Applications of fMRI in translational medicine and clinical practice Nat Rev, Neurosci 7 2006 732 744 (Pubitemid 44267497)
13. A.-H. Maehle, C.-R. Prüll, and R.F. Halliwell The emergence of the drug receptor theory Nat Rev, Drug Discov 1 2002 637 641 (Pubitemid 37361525)
14. H.P. Rang The receptor concept: pharmacology's big idea Br J Pharm 147 2006 S9 S16
15. D. Colquhoun The quantitative analysis of drug-receptor interactions: a short history Trends Pharmacol Sci 27 2006 149 157
16. T. Kenakin Principles: receptor theory in pharmacology Trends Pharmacol Sci 25 2004 186 192 (Pubitemid 38519909)
17. H.O. Schild pA, a new scale for the measurement of drug antagonism Br J Pharm 2 1947 189 206
18. H.O. Schild The use of drug antagonists for the identification and classification of drugs Br J Pharm 2 1947 251 258
19. T. Kenakin Drug efficacy at G protein-coupled receptors Annu Rev Pharmacol Toxicol 42 2002 349 379 (Pubitemid 34160530)
20. M. Corsi, P. Fina, and D.G. Trist Co-agonism in drug-receptor interaction: illustrated by the NMDA receptors Trends Pharmacol Sci 17 1996 220 222 (Pubitemid 26191243)
21. P.J. Conn, A. Christopoulos, and C.W. Lindsley Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat Rev, Drug Discov 8 2009 41 54
22. K. Leach, R.E. Loiacono, C.C. Felder, D.L. McKinzie, A. Mogg, D.B. Shaw, P.M. Sexton, and A. Christopoulos Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties Neuropsychopharmacology 35 2010 855 869
23. F. Monczor, N. Fernández, B.L. Legnazzi, M.E. Riveiro, A. Baldi, C. Shayo, and C. Davio Tiotidine, a histamine H2 receptor inverse agonist binds with high affinity to an inactive G-protein-coupled form of the receptor. Experimental support for the cubic ternary complex model Mol Pharmacol 64 2003 512 520 (Pubitemid 36910016)
24. A.P. Lightfoot, J.N. Kew, and J. Skidmore Alpha7 nicotinic acetylcholine receptor agonists and positive allosteric modulators Prog Med Chem 46 2008 131 171
25. K. Ebner, S.B. Sartori, and N. Singewald Tachykinin receptors as therapeutic targets in stress-related disorders Curr Pharmaceut Des 15 2009 1647 1674
26. E. Marshall Waiting for the revolution Science 331 2011 526 529
27. R.F. Service Proteomics ponders prime time Science 321 2008 1758 1761
28. K. Hollywood, D.R. Brison, and R. Goodacre Metabolomics: current technologies and future trends Proteomics 6 2006 4716 4723 (Pubitemid 44375842)
29. F.L. Kiechle, and C.A. Holland-Staley Genomics, transcriptomics, proteomics, and numbers Arch Pathol Lab Med 127 2003 1089 1097 (Pubitemid 37093256)
30. T. Furmark, L. Appel, A. Michelgrd, K. Wahlstedt, F. hs, S. Zancan, E. Jacobsson, K. Flyckt, M. Grohp, and M. Bergström Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo Biol Psychiatry 58 2005 132 142 (Pubitemid 41008130)
31. M. Wehling Translational medicine: science or wishful thinking? J Transl Med 6 2008 31 34
32. F.M. Marincola Translational medicine: a two-way road J Transl Med 1 2003 1 2
33. R.E. Becker, and N.H. Greig Lost in translation: neuropsychiatric drug development Sci Transl Med 2 2010 61rv6
34. P. Armitage Attitudes in clinical trials Statist Med 17 1998 2675 2683 (Pubitemid 28542688)
35. D. Berry The new math of clinical trials Science 303 2004 784 785
36. M. Keller, S. Montgomery, S.W. Ball, M. Morrison, D. Snavely, G. Liu, R. Hargreaves, J. Hietala, C. Lines, and K. Beebe Lack of efficacy of the substance P (Neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder Biol Psychiatry 59 2006 216 223 (Pubitemid 43208967)
37. K.R. Hess Statistical issues in clinical trial design Curr Oncol Rep 9 2007 55 59 (Pubitemid 46075634)